

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 April 2004 (01.04.2004)

PCT

(10) International Publication Number
WO 2004/026239 A2

- (51) International Patent Classification⁷: **A61K**
- (21) International Application Number:
PCT/US2003/029191
- (22) International Filing Date:
18 September 2003 (18.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/412,222 20 September 2002 (20.09.2002) US
10/366,538 12 February 2003 (12.02.2003) US
- (71) Applicant: **MOMENTUM PHARMACEUTICALS**
[US/US]; 11200 Wilcrest Green, Houston, TX 77042 (US).
- (72) Inventors: **GUENTHER, Harald, L.**; Burdweg 60,
CH-3095 Spiegel, Berne (CH). **GUENTHER, Han-
nelore, E.**; Burdweg 60, CH-3095 Spiegel, Berne (CH).
SORGENTE, Nino; 1832 Edgecliff Drive, Los Angeles,
CA 90026 (US).
- (74) Agent: **HAILE, Lisa, A.**; Gray Cary Ware & Freidenrich
LLP, 4365 Executive Drive, Suite 1100, San Diego, CA
92121-2133 (US).

- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: USE OF BETA GLUCANS FOR THE TREATMENT OF OSTEOPOROSIS AND OTHER DISEASES OF BONE RE-
SORPTION

(57) Abstract: The invention provides methods of using beta glucans to treat conditions associated with bone loss or low bone den-
sity as well as methods for promoting bone growth in situations where enhanced bone growth is desirable. In the invention methods
beta glucans are administered so as to enhance the development of osteoblasts and the inhibition of the development and recruitment
of osteoclasts. The inhibition of the recruitment and development of osteoclasts, coupled with the enhancement of osteoblast mat-
uration by beta glucans leads to decreased bone resorption and increased bone formation, making beta glucans ideal agents for the
treatment of osteoporosis and other bone resorption diseases.



WO 2004/026239 A2

USE OF BETA GLUCANS FOR THE TREATMENT OF OSTEOPOROSIS AND OTHER DISEASES OF BONE RESORPTION

Field of the Invention

[0001] The present invention relates to methods for treating conditions associated with bone loss or low bone density, particularly osteoporosis.

Background of the Invention

[0002] Bone is a specialized dynamic connective tissue that serves the following functions: (a) mechanical, support and site of muscle attachment for locomotion; (b) protective, for vital organs and bone marrow; (c) metabolic; as reserve of ions, especially calcium and phosphate, for the maintenance of serum homeostasis, which is essential for life. To carry out these functions efficiently bone must undergo continuous resorption and renewal, a process collectively known as remodelling. Thus, the mechanical and biological integrity of bone depends on its continuous destruction (resorption) and continuous rebuilding (formation) at millions of microscopic sites. During adult life bone remodelling is crucial to eliminate and replace structurally damaged or aged bone with structurally new healthy bone. To maintain the proper bone mass resorption and formation are kept in perfect equilibrium. With age the equilibrium between bone resorption and formation becomes altered, often in favor of resorption, resulting in a reduction in bone mass, deterioration of bone architecture, decreased resistance to stress, bone fragility and susceptibility to fractures. The compendium of these symptoms is referred to as osteoporosis.

[0003] Osteoporosis is a major health problem in Western society. And even though there are other diseases that result in reduction in bone mass, i.e. Paget's disease, osteoporosis is by far the most common and the disease that is the most costly in terms of health care. Since estrogen is a hormone that regulates bone metabolism directly and indirectly, the decrease in estrogen production in post-menopausal women and the decline with age in the production of androgen, which is enzymatically converted to estrogen in men,) is

responsible for the risk of osteoporosis, which is estimated to be 85% in women and 15% in men older than 45 years of age. In the United States it is estimated that 17 million post-menopausal women have lost 10% of their peak bone mass, 9.4 million have lost 25% and 5 million have suffered a fracture as a consequence of osteoporosis. Osteoporosis costs America's health care system more than \$14 billion a year from spine and hip fractures, which are often the first indication of the disease if it is left undiagnosed.

[0004] Osteoporosis, a disease endemic in Western society, typically reflects an imbalance in skeletal turnover, such that bone resorption exceeds bone formation. Bone resorption is a specific function of osteoclasts, which are multinucleated, specialized bone cells formed by the fusion of mononuclear progenitors originating from the hemopoietic compartment, more precisely from the granulocyte-macrophage colony-forming unit (GM-CFU). The osteoclast is the principal cell type, , to resorb bone, and together with the bone-forming cells, the osteoblasts, dictate bone mass, bone shape and bone structure. The increased activity and/or numbers of osteoclasts, relative to the activity and or numbers of bone-forming osteoblasts, dictates the development of osteoporosis and other diseases of bone loss.

[0005] Even though Paget's disease is not as common or as costly as osteoporosis -- it affects 3% of the population over 40, and 10% of the population over 80 years of age -- it is nonetheless a significant disease because aside from causing bone fractures it can lead to severe osteoarthritis and severe neurological disorders. Paget's disease is characterized by rapid bone turnover, resulting in the formation of woven bone a tissue type formed initially in the embryo and during growth and which is practically absence from the adult skeleton. Woven bone is marked by brittleness and therefore prone to fractures and bowing. Bones become enlarged and often interfere with blood flow and constrict nerves, resulting in many of the neurological symptoms associated with Paget's disease.

[0006] For a disease in which osteoclasts presumably resorb bone at abnormally high levels and osteoblasts form bone at normal levels, as in osteoporosis, the most reasonable therapeutic target would be the osteoclast: decreasing the number of osteoclasts and/or

the resorption activity of the osteoclasts, should restore the equilibrium between bone resorption and formation. And, in fact, the treatments now available for osteoporosis are intended to suppress bone resorption.

[0007] Osteoclasts are derived from the monocyte-macrophage family. Upon stimulation of the CFU-GM with macrophage colony stimulating factor (M-CSF) form promonocytes which are immature nonadherent progenitors of mononuclear phagocytes and osteoclasts. The promonocytes, may proliferate and differentiate along the macrophage pathway, eventually forming a tissue macrophage, or may differentiate along the osteoclast pathway, depending on the cytokines to which they become exposed. For example, the receptor activator NF- κ B ligand (RANKL) (Simonet WS, Lacey DL, Dunstan R, Kelley M, Chang M-S, Luethi R et al 1997 Osteoprotegerin, a novel secreted protein involved in the regulation of bone density. *Cell* 89:309-319) a cytokine expressed on the membrane surface of osteoblasts influences promonocytes to differentiate into osteoclasts rather than macrophages, while treatment with M-CSF drives the promonocyte to develop into macrophages. Since M-CSF and other cytokines i.e., interleukin-1 or TNF- α , that support expression of RANKL are products of macrophages it may be assumed that immunomodulating substances, which alter the expression of, these cytokines and growth factors, may affect not only macrophages but also osteoclasts.

[0008] It has long been known that beta glucans, and particularly the beta glucans from yeast, activate macrophages and have profound effects on the synthesis and levels of many cytokines, which in turn are responsible for modulating the function of many other cells. (Stoy, Y. "Macrophage biology and pathobiology in the evolution of immune responses: a functional analysis," *Pathobiology*, 69:179-211, 2001; Underhill DM, Ozinshy, A. "Phagocytosis of microbes: complexity in action," *Annu Rev Immunol.* 20:825-52, 2002; Purohit A, Newman SP, Reed MJ. "The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer," *Breast Cancer Res* 4:65-69, 2002; Ismail N, Olano JP, Feng HM, Walker DH. "Current status of immune mechanisms of killing intracellular organisms" *FEMS Microbiol Lett* 207:111-120, 2002; Hubel K, Dale DC, Liles WC. "Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony

stimulating factor, granulocyte-macrophage stimulating factor, macrophage colony stimulating factor and interferon gamma" *J. Inf Dis* 185:1490-1501, 2002.).

[0009] Even though there are a number of therapeutic modalities for osteoporosis, which include bisphosphonates (Fleisch H, "Development of biphosphonates," *Breast Cancer Res.* 4:30-34, 2002), estrogen (Spencer, CP, Stevenson. JC "Oestrogen and anti-oestrogen for the prevention and treatment of osteoporosis." In *Osteoporosis: Diagnosis and Management*, Martin Muniz, England, 1998, pp 111-123), or "Selective Estrogen Receptor Modulators," (SERMS) most of these have significant undesirable side-effects.

[0010] Glucans are polysaccharides consisting of glucose subunits. β -(1,6) branched β -(1,3) glucan is a naturally occurring class of polysaccharides that can be extracted from Baker's yeast and other yeast species, mushrooms, plants and some bacterial, lichen and algal species (reviewed in *Chemistry and Biology of (1 \rightarrow 3)- β -Glucans*, B.A. Stone and A.E. Clarke, 1992, La Trobe University Press, Australia). β -(1,6) branched (1,3) glucans have been shown to have immune enhancing and cholesterol-lowering capabilities. Yeast synthesizes at least three different types of beta glucans, a linear β -1,3-D-glucans, a linear β -1,6-D-glucan and a β -(1,6) branched β -(1,3) glucan. However, linear β -1,3-D and linear β -1,6-D-glucans do not activate or only marginally activate macrophages, NK cells or neutrophils.

[0011] As a class of polysaccharides, β -(1,6) branched β -(1,3) glucans are composed of a main chain of glucose subunits linked together in and branches linked to the main chain by a (1 \rightarrow 6) β glycosidic linkage. Yeast β -(1,6) branched β -(1,3) glucan is composed of mostly of a main chain of glucose units linked by (1 \rightarrow 3) beta glycosidic linkages (90% or more) with a variable number of relatively short side chains linked by β -(1 \rightarrow 6) glycosidic linkages (10% or less); the chemical name for this glucan is poly-(1,3)- β -D-glucopyranosyl-(1,6)- β -D-glucopyranose. There are several different types of beta glucans, which vary in backbone composition, branching, type of monomers or substituents, resulting in polysaccharides that have very different physical and biological properties (Metz, Ebert, and Weicher, *Chromatographia* 4:345,1970; Manners et al., The

structure of β -(1-3) D-glucan from yeast cell walls. *Biochem. J.* 135:19, 1973; US Patent No. 5,223,491).

[0012] Whereas all the β -1,3/1,6-D-glucans have been shown to activate the immune system of vertebrate as well as invertebrate organisms, the yeast-derived β -1,3/1,6-D-glucan is a most powerful activator of macrophages, NK cells, and neutrophils. Beta glucan from yeast activates the immune system by binding to a specific receptor on the cell membrane of macrophages (Czop and Kay, Isolation and characterization of β -glucan receptors on human mononuclear phagocytes. *J. Exp. Med.* 173:1511-1520, 1991). The activated macrophages increase their phagocytic and bactericidal activities as well as the production of a wide range of cytokines (Burgaletta, C and Golde, DW, in *Immune Modulation and control of neoplasia by adjuvant Therapy* (Chirigos, M.A., ed), pp195-200. Raven Press, NY, 1978; Sherwood et al., "Glucan stimulates production of antitumor cytolytic/cytostatic factors by macrophages," *J. Biol. Resp. Mod.*, 6:358-381; Sherwood, et al., "Enhancement of interleukins 1, and interleukins 2 production by soluble glucan"; Browder et al., "Beneficial effects of enhanced macrophage function in the trauma patient," *Ann. Surg.* 211:605-613). Enhanced function of macrophages, as well NK cells, appear responsible for a number of beneficial effects of yeast beta glucan, such as increased resistance of the host to infection by bacteria, viruses, fungi and protozoan parasites (Williams et al., "Protective effect of glucan in experimentally induced candidiasis," *J. Reticuloendot. Soc.* 23:479-490, 1978; Williams and DiLuzio. "Immunopharmacological modification of experimental viral diseases by glucan," *EOS JK Immunol Immunopharmacol* 5:78-82, 1985; Babineau et al. "A phase II multicenter, double blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PCG-glucan) in high risk surgical patients," *Arch. Surg.*, 129:601-609., 1994). In addition, the enhanced function of macrophages and NK cells appears to increase the host defenses against malignant tumors (Mansell et al. "Macrophage mediated destruction of human malignant cells in vivo," *J Natl Canc. Inst.* 54:571-576, 1975; Williams et al. "Chemoimmunotherapy of experimental hepatic metastasis," *Hepatology*, 7:1296-1304, 1985; Ueno. "Beta-1,3-D-glucan, its immune effect and its clinical use," *Jap. J. Soc. Terminal Systemic Dis.* 6:151-154, 2000).

[0013] Beta-1,3/1,6-D-glucan isolated from baker's or brewer's yeast (*Saccharomyces cerevisiae* strain) as well other yeasts, is insoluble, and furthermore the variability in the number of beta-(1,6) side chains makes it extremely difficult if not impossible to determine whether the beta-1,3/1,6-D-glucan is the branched beta-1,3/1,6-D-glucan or a mixture of beta-1,3-D-glucan plus beta-1,6-D-glucan, or a mixture of all three beta glucans. Yeast makes all three types of beta glucans. Since only the branched beta-1,3/1,6-D-glucan activates macrophages, it would be desirable to have pure beta-1,3/1,6-D-glucan; in addition, insoluble beta-1,3/1,6-D-glucan is difficult to formulate for parenteral or topical administration. It would be desirable to have a beta glucan that could be easily characterized, and which could be easily formulated for topical and parenteral administration. In addition, it would be of benefit for formulation purposes to have a lower molecular weight beta glucan that retains biological activity. A low molecular weight, soluble beta-1,3/1,6-D-glucan used topically would also be able to penetrate faster and, used parenterally, would very likely reach tissue macrophages faster, resulting in an earlier activation.

[0014] To date the soluble beta glucans that have been available are all of the high molecular weight variety, and for the major part these glucans were made soluble by chemical modifications or solubilized by sequential treatments with alkali/acid/alkali. A number of soluble glucans have been obtained by derivatization of the natural, insoluble beta-1,3/1,6-D-glucan compound, such as phosphorylation (U. S. Pat. Nos.: 4,739,046; 4,761,402), sulfation, amination (U.S. Pat. No.: 4,707,471) or methylation. A beta-1,3/1,6-D-glucan solubilized by sequential treatment with alkali/acid/alkali of insoluble beta-1,3/1,6-D-glucan (U.S. Pat. No. 5,849,720) has been shown to be effective in humans to control infections in surgical patients (Babineau et al. A phase II multicenter, double blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PCG-glucan) in high-risk surgical patients (*Arch. Surg.*, 129:601-609, 1994).

[0015] There is therefore a need for therapies to inhibit or prevent bone loss that have less or no side effects and offer more natural biological mechanisms.

SUMMARY OF THE INVENTION

[0016] The present invention is predicated on the surprising finding that beta glucans are able to suppress osteoclast development and may enhance the development of osteoblasts.

[0017] In one embodiment, the invention is directed to methods of treating conditions in which there is a loss or decrease in bone mass in mammals by administering a beta glucan, or a pharmaceutically acceptable salt thereof.

[0018] In particular this invention is directed to such methods wherein the condition is osteoporosis, Paget's disease, a bone defect, childhood idiopathic bone loss, alveolar bone loss, or bone fracture.

[0019] In another embodiment, the invention provides methods for promoting bone growth in a mammal in need thereof comprising administering to said mammal an effective amount of beta glucan, or a pharmaceutically acceptable salt of the beta glucan, so as to promote bone formation.

BRIEF DESCRIPTION OF THE FIGURES

[0020] Figures 1 A-C is a series of graphs showing the effect of beta glucan upon alkaline phosphatase of rat osteoblasts of different maturation.

[0021] Figure 2 is a graph showing inhibition of osteoclast-mediated resorption in vitro by osteoprotegerin (commercial product) and beta glucan.

[0022] Figure 3 is a graph showing inhibition of osteoclast formation by osteoprotegerin (commercial product) and beta glucan.

[0023] Figures 4 A-C is a series of graphs showing the effect of media conditioned by beta glucan-treated osteoblasts and fibroblasts on formation of TRAP⁺ multinucleated cells (MNC) and osteoclasts in vitro.

[0024] Figures 5 A-C is a series of graphs showing the effect of media conditioned by beta glucan-treated osteoblasts and fibroblasts on formation of osteoclastic resorption pits in vitro.

DETAILED DESCRIPTION OF THE INVENTION

[0025] The present invention provides methods and compositions for the treatment of osteoporosis, Paget's disease and other conditions which present with low bone mass or result in the loss of bone, particularly when the loss of such bone results from increased numbers of osteoclasts and/or increased bone resorbing activity of osteoclasts.

[0026] In the invention methods for treating a condition associated with low bone mass in a mammal an effective amount of beta glucan, or a pharmaceutically acceptable salt of the beta glucan, is administered so as to inhibit bone resorption and/or increase bone formation.

[0027] Methods for treating "secondary osteoporosis" are also included within the methods of this invention. "Secondary osteoporosis" includes glucocorticoid-induced osteoporosis, hyperthyroidism-induced osteoporosis, immobilization-induced osteoporosis, heparin-induced osteoporosis and immunosuppressive-induced osteoporosis in a vertebrate, e.g., a mammal (including a human being). These methods are carried out by administering to said vertebrate, e.g., mammal, a "secondary osteoporosis" treating amount of a beta glucan or a pharmaceutically acceptable salt thereof.

[0028] The inhibition of osteoclast activity in the invention methods can be the result of an inhibitory activity of the resorption mechanisms of the osteoclasts or can be the result of an inhibition of the number of osteoclasts recruited from precursor cells, or a combination of both. In an analysis of osteoclast recruitment, extremely low concentrations of beta glucan decreases the number of osteoclasts formed (Figure 2). At concentrations as low as 100 pg there is a decrease of 30% and at concentrations of 1 ng and 10 ng there is an inhibition of approximately 50%. Increasing the concentration of beta glucan does not increase the inhibition of osteoclast formation rather the effect

diminishes. This observation is consistent with the fact that beta glucan has its effect via a receptor and that high concentrations may lead to receptor down-regulation.

[0029] In osteoporosis, which affects mostly older individuals and particularly post-menopausal women, combined with increased bone resorption there is a slow-down in bone formation by osteoblasts, which occurs normally due to the aging process. As used in the invention methods of treatment, beta glucan enhances osteoblast formation, thus also increasing bone formation.

[0030] In another embodiment, the invention provides methods for promoting bone growth in a mammal in need thereof by administering thereto an effective amount of a beta glucan, or a pharmaceutically effective amount thereof. Conditions wherein promotion of bone growth is beneficial include strengthening a bone graft, inducing vertebral synostosis, enhancing long bone extension, enhancing bone healing following facial reconstruction, maxillary reconstruction and/or mandibular reconstruction in a vertebrate, e.g., a mammal (including a human being), and the like.

[0031] An "effective amount" of beta glucan for use in treating a condition associated with bone loss or in a condition wherein promotion of bone growth is beneficial is an amount sufficient to inhibit bone loss and/or increase bone formation or to inhibit osteoclast activity. Those of skill in the art will consider such factors as the mammal's age, level of activity, hormone balance, general health in determining the effective amount, which is tailored to the subject, for example by beginning with a low dosage and titrating the dosage to determine the effective amount. By the studies described herein it has been discovered that increasing the concentration of beta glucan does not necessarily increase the inhibition of osteoclast activity, and may actually reduced inhibition of osteoclast activity (Figure 1). At 100 pg the effect is similar to the effect obtained with bisphosphonates, which in various forms are used as drugs to control osteoporosis.

[0032] The phrase "condition(s) associated with low bone mass" refers to a condition where the level of bone mass is below the age specific normal as defined in standards by the World Health Organization" Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis (1994). Report of a World Health

Organization Study Group. World Health Organization Technical Series 843". Included in "condition(s) associated with low bone mass" are primary and secondary osteoporosis, as described above. Also included is periodontal disease, alveolar bone loss, post-osteotomy and childhood idiopathic bone loss. The phrase "condition(s) associated with low bone mass" also includes long term complications of osteoporosis such as curvature of the spine, loss of height and prosthetic surgery.

[0033] The phrase "condition(s) which present with low bone mass" also refers to a vertebrate, e.g., a mammal known to have a significantly higher than average chance of developing such diseases as are described above including osteoporosis (e.g., post-menopausal women, men over the age of 50). Other bone mass augmenting or enhancing uses include bone restoration, increasing the bone fracture healing rate, replacing bone graft surgery entirely, enhancing the rate of successful bone grafts, bone healing following facial reconstruction or maxillary reconstruction or mandibular reconstruction, prosthetic ingrowth, vertebral synostosis or long bone extension. Those skilled in the art will recognize that the term bone mass actually refers to bone mass per unit area, which is sometimes (although not strictly correctly) referred to as bone mineral density.

[0034] The methods of this invention may also be used in conjunction with orthopedic devices such as spinal fusion cages, spinal fusion hardware, internal and external bone fixation devices, screws and pins.

[0035] The term "treating", "treat" or "treatment" as used herein includes preventative (e.g., prophylactic), palliative and curative treatment. The methods of this invention result in bone formation resulting in decreased fracture rates. This invention makes a significant contribution to the art by providing methods that increase bone formation resulting in prevention, retardation, and/or regression of osteoporosis and related bone disorders.

[0036] By "pharmaceutically acceptable" it is meant the carrier, vehicle, diluent, excipients, and/or salt must be compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof by the route administered.

[0037] The expression "pharmaceutically acceptable salt" refers to such nontoxic anionic salts containing anions such as (but not limited to) chloride, bromide, iodide, sulfate, bisulfate, phosphate, acetate, maleate, fumarate, oxalate, lactate, tartrate, citrate, gluconate, methanesulfonate and 4-toluene-sulfonate, and the like, that can be injected into the body.

[0038] Beta glucan is a naturally occurring class of polysaccharides that can be extracted from Baker's yeast and other yeast species, mushrooms, plants and some bacterial, lichen and algal species (reviewed in Chemistry and Biology of (1→3)- β -Glucans, B.A. Stone and A.E. Clarke, 1992, La Trobe University Press, Australia). β -(1,6) branched (1,3) glucans have been shown to have immune enhancing and cholesterol-lowering capabilities. Yeast synthesizes at least three different types of beta glucans, a linear β -1,3-D-glucans, a linear β -1,6-D-glucan and a β -(1,6) branched β -(1,3) glucan. However, linear β -1,3-D-glucans and linear β -1,6-D-glucans do not activate or only marginally activate macrophages, NK cells or neutrophils. In one embodiment of the invention methods, the beta glucan retains the biological activity of macrophage activation, such as a water soluble 1→6 branched 1→3 beta glucan. In another embodiment, the beta glucan contains 2 to 20% beta 1→6 branching and/or has a molecular weight of about 1500 to about 100,000.

[0039] For example, a yeast beta-1,3/1,6-D-glucan suitable for use in practice of the invention methods can be obtained from the yeast *Saccharomyces cerevisiae*. Such a beta glucan can be derived from a yeast cell wall preparation containing mostly yeast beta-1,3/1,6-D-glucan or from purified yeast beta-1,3/1,6-D-glucan by enzymatic degradation with a beta endoglucanase as described herein. Other beta glucans also have anti-resorptive activity and are suitable for use in practice of the invention methods. For example, in Figure 3 it is evident that the insoluble yeast beta glucan (Nayad), a beta glucan isolated from the mushroom *Blazei agaricus* also inhibits pit formation by osteoclasts. Figure 4 shows that all beta glucans examined (yeast soluble and insoluble (Nayad), beta glucan from *Blazei agaricus*, *Yunzhi* beta glucan and even Zymosan, which

is a hot alcoholic extract of yeast with immuno-modulating activity, due to the beta glucan in Zymosan) are capable of inhibiting the formation of osteoclasts.

[0040] The utility of the beta glucans used in the methods of the present invention as medical agents in the treatment of conditions associated with low bone mass (e.g., osteoporosis) in vertebrates, e.g., mammals (especially humans and particularly female humans) is demonstrated by the activity in bone resorption assays as are known in the art and as described herein. Such assays also provide a means whereby the activities of beta glucans can be compared to each other and with the activities of other known compounds and compositions useful for treating such conditions. The results of these comparisons are useful for determining dosage levels in vertebrates, e.g., mammals, including humans, for the treatment of such diseases.

[0041] The preferred route of administration of the beta glucans as used in the invention methods is systemic administration, e.g., orally, subcutaneously, intramuscularly or via aerosol. For example, formulations or compositions containing a hydrolyzed beta glucan can be injected parenterally, for example by injection into the peripheral circulation.

[0042] In another embodiment, the invention provides methods for promoting bone growth in a mammal in need thereof by administering thereto an effective amount of a beta glucan, or a pharmaceutically effective amount thereof. Conditions wherein promotion of bone growth is beneficial include strengthening a bone graft, inducing vertebral synostosis, enhancing long bone extension, enhancing bone healing following facial reconstruction, maxillary reconstruction and/or mandibular reconstruction in a vertebrate, e.g., a mammal (including a human being), and the like.

[0043] An "effective amount" of beta glucan for use in treating a condition associated with bone loss or in a condition wherein promotion of bone growth is beneficial is an amount sufficient to inhibit bone loss and/or increase bone formation or to inhibit osteoclast activity. Those of skill in the art will consider such factors as the mammal's age, level of activity, hormone balance, general health in determining the effective amount, which is tailored to the subject, for example by beginning with a low dosage and

titrating the dosage to determine the effective amount. By the studies described herein it has been discovered that increasing the concentration of beta glucan does not necessarily increase the inhibition of osteoclast activity, and may actually reduced inhibition of osteoclast activity (Figure 1). At 100 pg the effect is similar to the effect obtained with a bisphosphonate, which in various forms are used as drugs to control osteoporosis.

[0044] The beta glucan used in the invention methods can be contained in a formulation comprising a carrier suitable as is known in the art to the desired mode of administration, i.e., injection into the peripheral circulation. The composition may also include one or more compounds known in the art to be beneficial to bone formation, such as calcium, fluoride, magnesium, boron, or a combination thereof.

[0045] Soluble beta-1,3/1,6-D-glucan for use in the invention methods of treating conditions in which there is a loss or decrease in bone mass in mammals or the need to promote bone formation can be produced and manufactured from yeast or other microorganisms containing beta-1,3/1,6-D-glucan using the following steps:

- a. Yeast cells or cell walls are treated with a base at high temperature to solubilize alkali soluble components of the cell
- b. After washing with water, the residue is treated with an acid at high temperature

Alternatively,

- a₁. Yeast cell walls are treated with an acid
- b₁. After washing water, the residue is treated with sodium hypochlorite
- c. After washing with water, the residue is hydrolyzed with a beta glucanase at a specific temperature
- d. The mixture is centrifuged and the residue discarded
- e. The supernatant is ultrafiltered through a membrane with a nominal weight cut-off of 100,000 daltons

- f. The effluent is ultrafiltered through a membrane with a nominal molecular weight cut-off of 1000 daltons
- g. The retentate is concentrated and suspended in 100% ethanol
- h. The precipitate is washed with ethanol and dried.
- i. If so desired, this material can further be purified and fractionated by ultrafiltration through a series of membranes with different molecular weight cut-offs or by chromatography.

[0046] The process of manufacture detailed here provides a soluble beta-1,3/1,6-D-glucan of low molecular weight, which retains the ability to activate macrophages. The manufacture of the soluble beta-1,3/1,6-D-glucan is achieved by first treating the organism containing beta-1,3/1,6-D-glucan (e.g., yeast cells or yeast cell walls) with alkali and acid solutions to remove non-beta glucan components, which makes the beta glucan available to the action of the enzyme. This treatment is then followed by enzymatic hydrolysis and purification of the solubilized beta-1,3/1,6-D-glucan.

[0047] Whole yeast cells or cell walls (*Saccharomyces cerevisiae*) are suspended in an alkaline solution and heated. The alkaline solution can be an alkali-metal or an alkali-earth metal hydroxide, such as sodium hydroxide or potassium hydroxide having a concentration from about 0.05 N to 10 N. This step is conducted at a temperature of 4°C to 150°C, but preferably at 80°C. This step can be conducted at normal atmospheric pressure or at an elevated pressure, but preferably at 15 psi and 121°C. The treatment time may vary from about 10 minutes to 48 hours depending on the strength of the alkali solution and the temperature and the type of organism. Once the alkali treatment is complete, the residue is separated from the solution by an appropriate method, such as filtration or centrifugation. This alkali can be repeated one time or more.

[0048] The residue is washed with water one or more times and then extracted with an acid, such as hydrochloric acid, formic acid, acetic acid or other. An acid solution of pH 1 to 5 is usually sufficient at a temperature 4°C to 150°C, for 15 minutes to 48 hours. The preferred conditions are extraction with acid is acetic acid at a concentration of 3% and at a temperature of 85°C for 45 minutes. The insoluble material is separated from the

solution by an appropriate procedure. The residue is then washed one or more time with water and again separated by an appropriate method.

[0049] Yeast cell walls can first be treated with an acid, such as hydrochloric acid, formic acid, acetic acid or other. An acid solution of pH 1 to 5 is usually sufficient at a temperature 4°C to 150°C, for 15 minutes to 48 hours. The preferred conditions are extraction with acid is acetic acid at a concentration of 4% at a temperature of 85 °C for 45 minutes. The insoluble material is separated from the solution by an appropriate procedure. The residue is then washed one or more times with water and again separated by an appropriate method.

[0050] The residue is then extracted with sodium hypochlorite at a concentration from 15 to 75 % at a temperature ranging from 4 °C to 150° C, for 15 minutes to 48 hours. The residue is then washed with water one or more times.

[0051] The residue is the treated with an enzyme that has endoglucanase activity at a temperature from 10 °C to 80° C, for 15 minutes to 48 hours depending on the temperature, liquid to solids ratio, and concentration of the enzyme. The soluble enzyme digest is separated from the undigested material by an appropriate technique, such as centrifugation, filtration, etc. The soluble digested material can then be fractionated into discrete fractions by ultrafiltration, chromatography, sedimentation, electrofocusing, etc.

[0052] The invention will now be illustrated by the following non-limiting examples.

EXAMPLE 1

Preparation of Soluble beta-1,3/1,6-D-glucan from yeast cells

[0053] *Saccharomyces cerevisiae* cells are added to 10 volumes of 1.5 N NaOH with stirring. The mixture is then heated at 60°C for 30 minutes. The heated mixture is then autoclaved for 15 minutes at 15 psi and 121°C. The mixture is cooled and the supernatant is separated from the residue by centrifugation. The residue is washed with 10 volumes

of water for 15 minutes with stirring. After separating the supernatant by centrifugation, 10 volumes of 3% acetic acid at 37°C are added to the residue and the mixture is heated at 85°C for 45 minutes with stirring. The mixture is cooled and the supernatant is separated from the residue by centrifugation. The residue, which is impure beta-1,3/1,6-D-glucan, is washed with water for 15 minutes with stirring.

[0054] The impure beta-1,3/1,6-D-glucan is suspended in 3 volumes of water and added to another 20-25 volumes of water at 40° C. To this mixture are added 100 ml of Viscozyme L beta-1,3-glucanase purchased from Novo Nordisk, Farnkliton, N.C. This mixture is stirred and heated to 80° C. The slurry is then pumped through a fiber filter unit equipped with a filter with a molecular weight cut-off of 100,000 daltons. The retentate is recycled continuously over a 10 hr period, always maintaining the volume constant in the reaction vessel by adding water at 80° C. The ultrafiltrate is collected continuously over the 10 hr period. Reducing sugar is checked in the ultrafiltrate every one liter collected. The ultrafiltrate is pumped through the inside of hollow fibers with a molecular weight cut-off of 1500, to dialyze of salt and low molecular weight pigments or sugars. Dialysis is carried out by pumping water through the outer shell of the hollow fiber unit at 800 ml/min. After 10 hours 14.5 liters of ultrafiltrate is collected. The ultrafiltrate is concentrated by reverse osmosis followed by concentration with a rotary evaporator. The beta-1,3/1,6-D-glucan is precipitated from concentrated in the cold overnight ultrafiltrate with 10 volumes of 95% ethanol. The precipitate is collected, washed with 95% ethanol and dried.

[0055] The dried precipitate can be further purified by chromatography (e.g. affinity, gel permeation, chromatofocusing, etc.), or filtration with membranes of varying molecular weight cut-offs (Vercellotti et al. "Chemistry of membrane separation processes in sugar industry applications," *Zuckerindustrie* 123:736, 1998).

[0056] Figure 1 shows an HPLC gel permeation chromatograph of the alcohol precipitate.

[0057] Table 1 shows a typical composition of the alcohol precipitated water soluble beta-1,3/1,6-D-glucan.

TABLE 1

<u>Component</u>	<u>%</u>
Total carbohydrate	98
Glucose	72
Mannose	16
Protein	4
Lipid	0
Ash	2

[0058] Table 2 shows some physical characteristics of the alcohol precipitated water soluble beta-1,3/1,6-D-glucan.

TABLE 2

Molecular Weight (Gel Permeation Chromatography)	12,000-60,000 daltons
Solubility	2.5gm/ml
Color in water	Light beige
Absorption at 280nm (E ^{1%})	2632
pH of a 1% solution in water	7.0
β (1→3) bonds (%)	83
β (1→6) bonds (%)	17
α (1→4) bonds (%)	None

[0059] Table 3 shows the activation of macrophages in vitro (increase in interleukin 1 and H₂O₂ production) by the soluble alcohol precipitated water soluble beta-1,3/1,6-D-glucan.

TABLE 3

	IL-1 ¹	Bb ² (ng)
Control	0.05	4.2
Zymosan ³	ND	13
WS100 ³	0.23	36

¹ Stimulation Index

² Bb released indicates activation of the Alternative Complement Pathway

³ Data is for 1mg/ml used in the assays

Example 2

In vitro Bio-Assay to Assess the Effect of Beta-Glucan on Osteoclast Formation and Activity by beta glucan

[0060] To determine the effect of beta glucan on osteoclast-mediated resorption a modification of the bioassay described by Collin et al was used (Collin P, Guenther HL, Fleisch H Constitutive expression of osteoclast-stimulating activity by normal clonal osteoblast-like cells: effects of parathyroid hormone and 1,25-dihydroxy-vitamin D₃. *Endocrinology* 131:1181-1187, 1992). The principle of the bioassay is based on cultivating freshly isolated disaggregated osteoclasts on elephant dentin (ivory) surfaces and measure the formation of resorption lacunae excavated by actively resorbing osteoclasts.

Example 3

Isolation and culture of osteoclasts

[0061] Osteoclasts were isolated from femurs of 1-day-old rats (Wistar) as outlined elsewhere (Collin P et al. 1992, see above). Briefly, after killing the animals, femurs were dissected freed of adherent soft tissue and subsequently cut across the epiphysis to remove the marrow. The femurs were then placed in a dish containing 1 ml MEM supplemented with 0.5% gentamicin. Osteoclasts were gently released from the femurs using in succession calibrated dental needles of size 20 and 30. Resulting osteoclast suspension was then brought to a volume of 8 ml with MEM. and 500 μ l of the cell preparation were added to eight ivory slices kept individually in plastic wells (2.0 x 1.0 cm). After 25-min incubation at 37 C and 5% CO₂/air, nonadherent cells were removed by lateral agitation. Next, eight slices for control and 8 for each treated group were individually transferred into single wells of a 24-well plastic tissue culture plate to which 500 μ l of either control or test media were added. The cultures were carried out in MEM at 37 C and 5% CO₂/air. After 24 h, cells cultured on ivory slices were washed with 0.5 ml PBS. Thereafter the cells were fixed and subsequently stained for TRAP according to instructions of the manufacturer (Sigma). Individual slices were then examined for TRAP+ multinucleated cells (MNC) containing at least three nuclei per cell. Following enumeration the TRAP+ MNC were removed by ultrasound in 70% propanol. Thereafter the dentine slices were washed, air-dried and sputter-coated with gold (SCD 004 Coater, Balzers, Liechtenstein). The number of resorption pits on each ivory slice was scored with a light microscope equipped with a tangential light, at a magnification x 200. A pit was defined as a depression in the ivory surface with a continuous rim and an area of at least 250 μ m². Pit areas were calculated from pit images that were captured by a camera attached to the reflected light microscope with the aid of image analysis software (NIH Image).

Example 4

Preparation of ivory slices

[0062] Elephant ivory (kindly obtained from Dr. B. Irrall, Bundesamt für Veterinärwesen, Berne Switzerland) was used as mineral substrate to assess osteoclast resorption activity. The ivory was cut into 4 x 4 x 0.1 mm slices with a Isomet low-speed saw (Buehler Instrument, Evanston, IL). Resulting slices were cleaned by ultrasound for 30 sec in de-ionized water. Thereafter the pieces were air-dried, gas sterilized and subsequently degassed under vacuum for 24 h.

Example 5

Effect of beta Glucan on Bone Resorption through Osteoblast as Assesory Cells

[0063] Based on the fact that the osteoclast suspension used to assay bone resorption in vitro, is contaminated with other cell types noticeably with osteoblasts, made it necessary to examine whether osteoblasts act as accessory cells in the beta glucan effect on osteoclastic resorption.

[0064] Fully functionally clonal osteoblastic CRP10/30 and clonal preosteoblastic CRP5/4 cells were cultured with and without different concentrations of "beta-G" in the presence of 2% FBS. After 5 hours incubation, media were replaced and the cells were cultured for an additional 24 hours in the absence of the test substances. The conditioned media were collected and concentrated to 1/10 of its volume using an ultrafiltration device equipped with a filter with a molecular cutoff of 1k. The concentrated conditioned media were reconstituted to their original volumes with fresh culture medium and subsequently tested on isolated osteoclast as described above.

[0065] The results of scoring for the number of osteoclasts (TRAP+ multinucleated cells) and resorption lacunae (pits) show that at concentrations of 100 pg there is an

inhibition of pit formation that could not be observed in control cultures (nontreated osteoclasts). Increasing the concentration of beta glucan does not increase inhibition of osteoclast activity; in fact, actually a reduction of the inhibition was measured. (Figure 1). At 100 pg the effect is similar to the effect obtained with a biphosphonate; biphosphonates are used in various forms as drugs to control osteoporosis.

[0066] An inhibition of the number of resorption pits can result from an inhibitory effect upon osteoclast resorption activity (pits formed/osteoclast, from inhibition of the number of osteoclasts recruited from precursor cells, or a combination of both. In an analysis of osteoclast recruitment, extremely low concentrations of beta glucan decreases the number of osteoclasts formed (Figure 2). At concentrations as low as 100 pg there is a decrease of 30%, and at concentrations of 1 ng and 10 ng there is an inhibition of approximately 50%. Increasing the concentration of beta glucan does not increase inhibition of osteoclast formation, but rather the effect diminishes. This observation is consistent with the fact that beta glucan has its effect via a receptor and that high concentrations lead to receptor down regulation. In addition, based on the ratio of pits/osteoclast (resorption activity) and the average resorption (areas/pit of treated and control cultures), it is concluded that beta glucan inhibits the recruitment of osteoclasts rather than the resorption activity.

[0067] In osteoporosis, which affects mostly older individuals and particularly post-menopausal women, combined with increased bone resorption there is a slow-down in bone formation by osteoblasts, which occurs normally due to the aging process. Beta glucan moderately enhances differentiation and osteoblast formation, thus supporting bone formation.

[0068] Other beta glucans (prepared from different sources) also generate anti-resorptive activity. In Figure 3 it is evident that the insoluble yeast beta glucan (Nayad), a beta glucan isolated from the mushroom *blazei agaricus* also inhibits pit formation. The inhibition appears to be the result of inhibition of osteoclast formation. Figure 4 shows that in all beta glucans examined (yeast) soluble and insoluble (Nayad), beta glucan from *Blazei agaricus*, *Yunzhi* beta glucan and even Zymosan, which is a hot alcoholic extract

of yeast with immuno-modulating activity, due to the beta glucan in Zymosan) are capable of inhibiting the formation of osteoclasts.

[0069] Both Figure 3 and Figure 4 show that the most potent inhibitor is the soluble yeast beta glucan.

[0070] Beta glucan also modulates the development of osteoblasts. Clonal osteoblastic CRP10/30 cells, which are mature functional osteoblasts, and clonal osteoblastic CRP5/4 cells, which are immature osteoblasts, were cultured in the presence of soluble beta glucan prepared as described herein. When the cells reached confluence, alkaline phosphatase was measured in the two types of cells. Figure 5 shows that the alkaline phosphatase of the mature osteoblastic cells was not affected; whereas the alkaline phosphatase in the immature osteoblastic cell increased (Figure 6), indicating that beta glucan stimulates the development of immature osteoblastic cells (CRP5/4) to mature osteoblasts.

[0071] Although the invention has been described with reference to the presently preferred embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

What is claimed is:

1. A method of treating a condition associated with low bone mass in a mammal comprising administering to said mammal an effective amount of water-soluble or water-insoluble beta glucan, or a pharmaceutically acceptable salt of the beta glucan, or a pharmaceutical acceptable derivative, so as to inhibit bone resorption.
2. The method of claim 1, wherein the beta glucan is derived from yeast, mushroom, plant, and bacterial beta glucan.
3. The method of claim 1, wherein the beta glucan is extracted from yeast.
4. The method of claim 3, wherein the yeast is *Saccharomyces cerevisiae*.
5. The method of claim 1, wherein the beta glucan is water soluble.
6. The method of claim 1, wherein the beta glucan activates macrophages.
7. A method of claim 5, wherein the water soluble beta glucan is a straight chain 1→6 linked glucan.
8. A method of Claim 5, wherein the water soluble beta glucan is a straight chain 1→3 linked glucan.
9. A method of claim 5, wherein the water soluble beta glucan is a 1→6 branched 1→3 beta glucan.
10. The method of claim 7, wherein the beta glucan activates macrophages.
11. A method of claim 1, wherein the beta glucan contains 2 to 20% beta 1→6 branching.

12. The method of claim 1, wherein the beta glucan has a molecular weight of about 1500 to about 100, 000.
13. The method of claim 10, wherein the beta glucan is a yeast beta-1,3/1,6-D-glucan.
14. The method of claim 11, wherein the yeast is *Saccharomyces cerevisiae*.
15. The method of claim 1 wherein said condition is selected from osteoporosis, Paget's disease, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, alveolar bone loss, and bone loss associated with periodontitis.
16. The method of claim 1, wherein the condition is osteoporosis.
17. The method of claim 1, wherein the condition is secondary osteoporosis and the effective amount is a secondary osteoporosis treating amount of a beta glucan or a pharmaceutically acceptable salt thereof.
18. The method of claim 15, wherein the secondary osteoporosis is selected from glucocorticoid-induced osteoporosis, hyperthyroidism-induced osteoporosis, immobilization-induced osteoporosis, heparin-induced osteoporosis and immunosuppressive-induced osteoporosis.
19. The method of claim 1, wherein the beta glucan is contained in a composition further comprising a carrier.
20. The method of claim 19, wherein the carrier is suitable for systemic administration the composition is administered systemically.
21. The method of claim 20, wherein the composition is injected parenterally.

22. The method of claim 18, wherein the beta glucan is administered by injection.
23. The method of claim 19, wherein the carrier is suitable for oral administration and the composition is administered orally.
24. The method of claim 23, wherein the composition further comprises a compound selected from Vitamin D, calcium, fluoride, magnesium, boron, or a combination thereof.
25. The method of claim 24, wherein the composition further comprises Vitamin D or one of its forms.
26. The method of claim 24, wherein the composition further comprises calcium.
27. The method of claim 24, wherein the composition further comprises fluoride.
28. The method of claim 24, wherein the composition further comprises magnesium.
29. A method for promoting bone growth in a mammal comprising administering to said mammal an effective amount of beta glucan, or a pharmaceutically acceptable salt of the beta glucan, so as to promote bone formation.
30. The method of claim 29, wherein the method promotes healing of a bone fracture.
31. The method of claim 29, wherein the condition is selected from strengthening a bone graft, inducing vertebral synostosis, enhancing long bone extension, and enhancing bone healing following facial reconstruction, maxillary reconstruction and/or mandibular reconstruction.
32. The method of claim 29, wherein the beta glucan is selected from yeast, mushroom, plant, and bacterial beta glucan.

33. The method of claim 29, wherein the beta glucan is extracted from yeast.
34. The method of claim 33, wherein the yeast is *Saccharomyces cerevisiae*.
35. The method of claim 33, wherein the beta glucan is water soluble.
36. The method of claim 27, wherein the beta glucan activates macrophages.
37. A method of claim 35, wherein the water soluble beta glucan is a 1→6 branched 1→3 beta glucan.
38. The method of claim 37, wherein the beta glucan activates macrophages.
39. A method of claim 2, wherein the beta glucan contains 2 to 20% beta 1→6 branching.
40. The method of claim 23, wherein the beta glucan has a molecular weight of about 1500 to about 500,000 .
41. The method of claim 38, wherein the beta glucan is a yeast beta-1,3/1,6-D-glucan.
42. The method of claim 39, wherein the yeast is *Saccharomyces cerevisiae*.
43. The method of claim 27, wherein the beta glucan is contained in a composition further comprising a carrier.
44. The method of claim 43, wherein the carrier is suitable for systemic administration the composition is administered systemically.
45. The method of claim 44, wherein the composition is injected parenterally.

46. The method of claim 45, wherein the beta glucan is administered by injection.
47. The method of claim 43, wherein the carrier is suitable for oral administration and the composition is administered orally.
48. The method of claim 47, wherein the composition further comprises a compound selected from calcium, fluoride, magnesium, boron, or a combination thereof.

Effect of "Beta-G" upon Alkaline Phosphatase of Rat Osteoblasts of Different Maturation





FIGURE 1

2/5

Osteoprotegerin (Commercial Product) and Beta-G Inhibit Osteoclast-mediated Resorption (Pit Formation), in vitro




* $p < 0.05$

*** $p < 0.001$ vs Ctrl + FBS

FIGURE 2

3/5

Osteoprotegerin (Commercial Product) and Beta-G Inhibit Osteoclast Formation, TRAP+ MNC, in vitro




**p < 0.05

***p < 0.001 vs Ctrl + FBS

FIGURE 3

4/5

**Effect of Media Conditioned by Beta-G-treated
Osteoblasts and Fibroblasts Upon Formation of
TRAP+multinucleated Cells (MNC), Osteoclasts,
*in vitro***




Ctrl - control
CT - calcitonin

FIGURE 4

5/5

Effect of Media Conditioned by Beta-G-treated Osteoblasts and Fibroblasts upon Formation of Osteoclastic Resorption Pits, *in Vitro*



Ctrl - control
CT - calcitonin

FIGURE 5